Drugs / KMB-17
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01712906 | Oct 2012 → Apr 2013 | mumps infectious disease | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01512706 | Jul 2011 → Jan 2012 | — | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KMB-17 | “Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.” NCT01712906 ↗1“A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been licensed by SFDA in China, Dec. 2010.” NCT01512706 ↗ |
| Modality | Vaccine | “formalin-inactivated EV71 vaccine” NCT01512706 ↗ |